Colorectal cancer represents an increasing problem and is responsible for about 16,000 deaths per year in Italy. Fluorouracil represents the most widely used agent, but therapeutic responses have remained consistently discouraging. The overall response rates for fluorouracil as a single agent range from 5% to 15%, and the addition of biochemical modulators, although able to improve response rate, has not been shown conclusively to prolong survival.
Methods
In recent years, several new compounds characterized by a high therapeutic index, optimal absorption through the gastrointestinal tract when administered orally and selective hepatic metabolization have been synthesised. In this review we analyzed published data on new fluoropyrimidines in an attempt to better define their role and to evaluate any significant improvement over fluorouracil.
Results
Athough no sure advantage over fluorouracil has been detected, interesting results have been reported for fluorouracil analogs with alternative routes of administration such as oral or intra-arterial chemotherapy.
Conclusions
Further studies, possibly randomized, should also measure quality of life and treatment-related costs in order to define their real advantage over fluorouracil in the palliation of advanced colorectal cancer.
Abele R., Alberto P., Kaplan S., Siegenthaler P., Hofmann V., Ryssel H.J., Hartmann D., Holdener E.E., Cavalli F. for the Swiss Group for Clinical Cancer Research:Phase II study of doxyfluridine in advanced colorectal adenocarcinoma. J. Clin. Oncol., 1: 750–754, 1983.
2.
AlbertoP., AbeleR., MermillodB., WeberW., CavalliF.: Phase I, II and III trials of intravenous 5′-deoxy-5-fluorouridine. In: Fluoropyrimidines in Cancer Therapy.KimuraK., FujiiS., OgawaM., BodeyG.P., AlbertoP. (Eds.) pp. 175–185, Excepta Medica, Amsterdam, 1984.
3.
AlbertoP., MermillodB., GermanoG., KaplanS., WeberW., JossR., StpatiB., MartzG., CavalliF.: A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur. J. Cancer Clin. Oncol., 24: 559–563, 1988.
4.
Allen-MershT.G., EarlamS., FordyC., AbramsK., HoughtonJ.: Quality of life and survival with continuous hepatic artery floxuridine infusion of colorectal liver metastases. Lancet, 344: 1255–1260, 1994.
5.
ArmstrongR.D., DiasioR.B.: Selective activation of 5′-deoxy-5-fluorouradine by tumor cells as a basis for improved therapeutic index. Cancer Res., 41: 4891–4894, 1981.
6.
AuJ.L., FriedmanM.A., SadeedW.: Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat. Rep., 63: 343–350, 1979.
7.
BajettaE., ColleoniM., Di BartolomeoM., NolèP., NelliP., DociR., de BraudF., Gallo StampinoC.: Doxifluridine: an active agent in advanced colorectal cancer (CRC) (abstract). Proc. Am. Soc. Clin. Oncol., 13: 554, 1994.
8.
BajettaE., ColleoniM., RossoR.: Prospective randomized trial comparing fluorouracil vs. doxifluridine for the treatment of advanced colorectal cancer. Eur. J. Cancer, 29: 1658–1663, 1993.
9.
BergerS.H., BarbourK.W., BergerF.G.: A naturally occurring variation in thymidylate synthetase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol. Pharcol.34: 480–484, 1988.
10.
BollangW., HartmannH.R.: Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur. J. Cancer, 16: 427–432, 1980.
11.
BurokerT., Padilla GroppeC.: Phase II evaluation of ftorafur. in previously untreated colorectal cancer, a Southwest Oncology Group Study. Cancer, 44: 48–51, 1979.
12.
ChangA.E., SchneiderP.D., SugarbakerP.H.: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann. Surg., 206: 685–693, 1987.
13.
ClarkJ.L., BergerS.H., MittelmanA., BergerF.G.: Thymidylate synthetase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat. Rep., 71: 261–265, 1987.
14.
CollinsJ.M.: Pharmacologic rationale for regional drug delivery J. Clin. Oncol., 2: 498–504, 1984.
15.
Di BartolomeoM., BajettaE., SommaL., LeoA., Del VecchioM., PandolfiA.: Oral doxifluridine and low-dose leucovorin in gastrointestinal tumors (abstract). Proc. 2° International Conference of Gastrointestinal Malignancies, Cologne, p. 39, 1995.
16.
EnsmingerW.D., RosowksyA., FlasoV.: A clinical pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res., 38: 3784–3792, 1978.
17.
ErlichmanC.: Fluorouracil/leucovorin study update. J. Clin. Oncol., 9: 2076, 1991.
18.
FalconeA., PfannerE., RicciS., BertucelliM., CianciC., CarraiM., De MarcoS., CeribelliA., BarduagniM., CalabresiF., CorneliaG., SarcinaR., LorussoV., Gallo StampinoC., PandolfiA., BruzziP., ConteP.F.: Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. Ann. Oncol., 5: 760–762, 1994.
19.
FriedmanM.A., IgnoffoR.J.: A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat. Rev., 7: 205–213, 1980.
20.
Gonzales BaronM., FeliuJ., De La GandaraI., ColmenarejoA., JalonJ.I., ChaconJ.I., BlancoE., JuarezF., ZamoraP., EspinosaE., OrdonezA., Garcia GironC., GarridoP., Garcia de PeredesM.L.: Phase II trial of uracil-tegafur (UFT) and leucovorin (LV) in advanced colorectal cancer (abstract). Proc. Am. Soc. Clin. Oncol., 13: 601, 1994.
HeidelbergerC., DanenbergP.V., MoranR.G.: Fluorinated pyrimidines and their nucleosides. Adv. Enzymol., 54: 57–119, 1983.
23.
HoD.H., CovingtonW.P., PazdurR.: Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab. Distribution, 20: 936–940, 1992.
24.
KemenyN., ContiJ.A., CohenA., CampanaP., HuangY., Ji ShiW., BotetJ., PulliamS., BertinoJ.R.: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol., 12: 2288–2295, 1994.
25.
KemenyN., DalyJ., ReichmanB., GellerN., BotetJ., OdermanP.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann. Intern. Med., 107: 459–465, 1987.
26.
MalikS.T.A., TalbotD., ClarkeP.I.: Phase II trial of UFT in advanced colorectal and gastric cancer. Br. J. Cancer, 62: 1023–1025, 1990.
27.
MartinJ.K.Jr., O'ConnellM.J., WieandH.S., FritzgibbonsR.J.Jr., MaillardJ.A.: Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch. Surg., 125: 1022, 1990.
28.
MiniE., MorosonB.A., BertinoJ.R.: Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancemant by leucovorin. Cancer Treat. Rep., 71: 381–389, 1987.
29.
MitomiT., TsuchiyaS., HikiY., NotoT., OgawaA.: A randomized controlled study on adjuvant chemotherapy with UFT in curatively resected colorectal cancer (abstract). Proc. Am. Soc. Clin. Oncol., 12: 225, 1993.
30.
MurakamiM., OtaK.: Clinical results of UFT therapy of malignant tumors under cooperative study. Jpn. J. Cancer Chemother., 7: 1579–1586, 1980.
31.
NiederhuberJ.E.: Arterial chemotherapy for metastatic colorectal cancer in the liver. Conference Advances in Regional Cancer Therapy. Giessen, West Germany, 1985.
32.
O'ConnellM.J.: Is hepatic infusion of chemotherapy an effective treatment for liver metastases? No. In: Important Advances in Oncology, De VitaV.T.Jr., HellmanS., RosenbergS.A. (Eds.) pp. 229–234, 1992.
33.
OtaK.: Multicentre cooperative phase II study of 5′-deoxy-5-fluorouridine in the treatment of colorectal cancer. J. Int. Med. Res., 16: 19B–20B, 1988.
34.
OtaK., TaguchiT., KimuraK.: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333–338, 1988.
35.
PazdurR., LassereV.R., AjaniJ.A., SugarmanS.M., PattY.Z., JonesD.V., MarkowitzA.B., AbbruzzeseJ.L., BreadyB., LevinB.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296–2300, 1994.
36.
PiedboisP., BuyseM., BlijamG., GlimeliusB., HerrmannR., ValoneF.: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol., 12: 960–969, 1994.
37.
RougierP., LaplancheA., HuguierM.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J. Clin. Oncol., 10: 1112–1118, 1992.
38.
RustumY.M.: New approaches for modulation of 5-fluorouracil (abstract), Proc. 2° Intern. Conf. of Gastrointestinal Malignancies, p. 39, 1995.
39.
SommadossiJ.P., AubertC., CanoJ.P., GouveiaJ., RibaudP., MatheG.: Kinetics and metabolism of a new fluoropyrimidine, 5′-deoxy-5-fluorouridine, in humans. Cancer Res., 43: 930–933, 1983.
40.
TraveF., CanobbioL., AuJ.L.S., RustumY.M.: Role of administration route in the therapeutic efficacy of doxifluridine. J. Natl. Cancer Inst., 78: 527–531, 1987.
41.
ValdiviesoM., BodeyG.P., GottliebJ.A.: Clinical evaluation of ftorafur. Cancer Res., 36: 1821–1824, 1976.
42.
WagmanL.D., KemenyM.M., LeongL., TerzJ.J.: A prospective randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J. Clin. Oncol., 8: 1885–1893, 1990.
43.
WatanabeH., YamamotoS., NaitoT.: Clinical results of oral UFT therapy under a cooperative study. Jpn. J. Cancer Chemother., 7: 1588–1596, 1980.
44.
WeissG.R., GarnickM.B., OsteenR.T.: Long-term hepatic arterial infusion of 5′-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J. Clin. Oncol., 1: 337–344, 1983.
